Strategy for designing a synthetic tumor vaccine: Multi-component, multivalency and antigen modification

11Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines. © 2014 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Huang, Z. H., Sun, Z. Y., Gao, Y., Chen, P. G., Liu, Y. F., Chen, Y. X., & Li, Y. M. (2014, July 15). Strategy for designing a synthetic tumor vaccine: Multi-component, multivalency and antigen modification. Vaccines. MDPI AG. https://doi.org/10.3390/vaccines2030549

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free